There are provided a coating composition for applying inkjet printing thereto to form a marked preparation, the composition providing good ink affinity, suppression of ink bleed, and excellent gloss; and others. More specifically, there are provided a composition for applying inkjet printing thereto to form a marked preparation, the composition including a water-soluble cellulose ether having a viscosity at 20 C. of from 2 to 50.0 mPa.Math.s, as determined in 2% by mass aqueous solution, polyvinyl alcohol, and a solvent, wherein a mass ratio of the water-soluble cellulose ether to the polyvinyl alcohol is from 99.0:1.0 to 55.0:45.0; a method for producing a preparation marked with aqueous ink, including a coating step of coating an object with the composition to form a coating layer, and a printing step of inkjet-printing on the coating layer with aqueous ink to obtain a preparation marked with aqueous ink; and others.

The objective of the present invention is to provide a capsule filling composition which can stably produce a capsule formulation by suppressing the flow of components out of the capsule body during capsule filling, regardless of the compressibility of an active ingredient such as drugs and health foods, so that a favorable capsule filling can be achieved; and a method of producing a capsule formulation with the use of such a capsule filling composition, as well as a capsule formulation. The objective is achieved by a method of producing a capsule formulation, comprising subjecting a capsule filling composition containing an active ingredient and a cellulose ether powder to a funnel system powder filling or a die-compression system powder filling to obtain the capsule formulation, and the like.

The present invention provides a band seal for hard capsules filled with PEG, particularly a low-molecular-weight PEG, PEG 200 to 600, the band seal being capable of effectively preventing content leakage through the gap between the body and cap of the capsule; and a liquid for preparing the band seal. The present invention further provides a hard capsule filled with PEG, particularly a low-molecular-weight PEG, PEG 200 to 600, the filled capsule being prevented content leakage through the gap between the body and cap of the capsule. The band seal can be prepared using a polyvinyl alcohol, a polyvinyl alcohol copolymer, or a mixture thereof as a main component.

The present disclosure relates to a composition suitable for a flavored banding portion of a tamper-evidence, two-part capsule and to the tamper-evident, two-part capsule having a flavored banding portion. The composition suitable for the flavored capsule banding portion includes a gelling agent, a surfactant, and a flavor system including a sweetener and a flavor configured to provide a capsule band that is effective to provide tamper evidence to a two-part capsule.

The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.

The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.

The present disclosure is related to a method of producing a capsule. The method includes providing a mold, depositing parylene on the mold to form a parylene layer, scoring the parylene layer, and coating the parylene layer with a polymer to produce a capsule.

An injection-molded shell of a dosage form of good quality is producible by a) providing a composition comprising i) from 25 to 90 weight percent of ethylcellulose, ii) from 7.5 to 60 weight percent of a polysaccharide or polysaccharide derivative being different from ethylcellulose, and iii) from 2.5 to 50 weight percent of at least one component being different from polysaccharides and polysaccharide derivatives, based on the total weight of the composition, with the proviso that the composition comprises zero or not more than 10 weight percent of gelatin and zero or not more than 10 weight percent of a polymer comprising homo- or copolymerized acrylic acid, homo- or copolymerized methacrylic acid, a homo- or copolymerized acrylate or a homo- or copolymerized methacrylate, and b) subjecting the composition to shearing and heat to plasticize the composition and injection-molding the plasticized composition into a three-dimensional shell of a dosage form.

The invention is to provide a method for producing a soft capsule type external preparation (and a softening liquid (L) used for the production thereof, and an external preparation composed of such a capsule body (C)) which can be stably stored and leaves no film residues when rubbed with the finger when used as an external preparation although the external preparation is structured only as a capsule body (C) substantially having no external solution. An original capsule body (c) in which at least the external surface region inside an alginate capsule is present in the form of a polyvalent metal alginate is contacted with a softening liquid (L) composed of an aqueous solution comprising both a basic amino acid (1) and an acid (2) selected from an organic acid or a phytic acid, thereby impregnating the softening liquid (L) into the original capsule body (c) to obtain the capsule body (C).

The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.